Summary
Background The unprecedented rapid development of vaccines against the SARS-CoV-2 virus creates in itself a new challenge for governments and health authorities: the effective vaccination of large numbers of people in a short time and, possibly, with shortage of vaccine doses. To whom vaccinate first and in what sequence, if any at all, to avoid the most fatalities remains an open question.
Methods A compartmental model considering age-related groups was developed to evaluate and compare vaccine distribution strategies in terms of the total avoidable fatalities. Population groups are established based on relevant differences in mortality (due to e.g. their age) and risk-related traits (such as their behaviour and number of daily person-to-person interactions). Vaccination distribution strategies were evaluated for different vaccine effectiveness levels and population coverage in a case study for Spain.
Findings Our results unambiguously show that planning vaccination by priority groups can achieve dramatic reductions in total fatalities compared to no prioritisation. Our results also indicate that the best strategy for vaccine distributions appears to be to prioritise groups with the highest number of daily person-to-person interactions. This is due to the importance of the avoided subsequent infections inflicted on the rest of the population by those in those groups.
Interpretation These results are in direct contradiction with several published guidelines for COVID-19 vaccination and therefore highlight the importance of conducting an open comprehensive and thorough analysis of this problem leaving behind possible preconceptions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Khalifa University (Grant 8474000317 CRPA-2020-SEHA) and the Government of Abu Dhabi
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
New sections have been added as well as the results for vaccination under scarcity of vaccines.
Data Availability
The Matlab source code and the Excel files containing all inputs and parameters used are fully available on demand.
